EBT-106

N/A

Report date: 2025/12/12 17:32:26

Base Information

Drug NameEBT-106
Drug Alias NameLNP-delivered CRISPR/CasX nuclease gene editing therapy (Excision BioTherapeutics)EBT-106
ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR
Mechanisms of ActionHepatitis B virus replication inhibitors
TargetsUpdating
Therapy Area/IndicationsHepatitis B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesExcision BioTherapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesExcision BioTherapeutics Inc
Inactive CompaniesN/A
Active IndicationsHepatitis B
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A